Answers are grounded in this paper and cite their sources.
Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are clonal hematopoietic disorders, with ET representing the most common Philadelphia chromosome–negative MPN in Korea. Since the previous Korean MPN guideline was published in 2020, the field has advanced considerably: diagnostic criteria have been further refined, the molecular landscape informing prognosis and treatment decisions has broadened, and new agents have become available. These developments have created a need to update the previous recommendations for the Korean clinical context. These expert consensus recommendations were developed by the Korean Society of Hematology MPN working Party to provide practical, evidence-informed recommendations for the risk-adapted management of PV, ET, and MF in Korean clinical practice. Recommendations are based on a comprehensive review of current international guidelines, including those of the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN), alongside emerging data from Korean and Asian patient populations. They address risk stratification frameworks, treatment goals evolving from hematologic response toward molecular response, and therapeutic options including phlebotomy, aspirin, cytoreductive agents, and allogeneic hematopoietic stem cell transplantation. Special clinical situations, including MPN in pregnancy and advanced-phase disease (accelerated and blast phase), are also addressed. These recommendations aim to support individualized, biology-informed treatment decisions, and to facilitate the integration of evolving therapeutic strategies into routine Korean hematology practice.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: